TransCode Therapeutics, Inc. Common Stock

Shares of TransCode Therapeutics, Inc. Common Stock (RNAZ) are trading at $1.69. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (167.1%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, RNAZ appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Sep 11, 2026.